000112760 001__ 112760
000112760 005__ 20230519145620.0
000112760 0247_ $$2doi$$a10.3390/jcm10204634
000112760 0248_ $$2sideral$$a127560
000112760 037__ $$aART-2021-127560
000112760 041__ $$aeng
000112760 100__ $$aGimeno-Orna, J.A.$$uUniversidad de Zaragoza
000112760 245__ $$aAssociation of the kdigo risk classification with the prevalence of heart failure in patients with type 2 diabetes
000112760 260__ $$c2021
000112760 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112760 5203_ $$aThe objectives of this study were to determine the main characteristics associated with the presence of heart failure (HF) in patients with type 2 diabetes (T2DM), and specifically to assess the association of the risk classification proposed by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines with HF. The DIABET-IC study is a multicentre, observational, prospective and analytical study in T2DM patients recruited in Spanish hospitals. This work, which features a cross-sectional design, has been conducted with the data obtained at the inclusion visit. The main dependent variable analysed was the presence of HF. The predictive variables evaluated were the demography, clinic, laboratory testing (including natriuretic peptides) and echocardiography. Patients were classified according to the number of vascular territories with atherosclerotic involvement and the KDIGO risk category. Multivariate logistic regression models were performed to determine the risk posed by the various baseline variables to present HF at the time of study inclusion. The study included 1517 patients from 58 hospitals, with a mean age of 67.3 (standard deviation (SD): 10) years, out of which 33% were women. The mean DM duration was 14 (SD: 11) years. The prevalence of HF was 37%. In a multivariate analysis, the independent predictors of HF were in-creased age (odds ratio (OR) per 1 year = 1.02; p = 0.006), decreased systolic blood pressure (OR per 1 mmHg = 0.98; p <0.001), decreased haemoglobin (OR per 1 g/dL = 0.86; p <0.001), the presence of obstructive sleep apnoea (OR = 1.61; p = 0.006), the absence of hepatic steatosis (OR = 0.59; p = 0.016), the severity of atherosclerotic involvement (OR 1 territory = 1.38 and OR >1 territory = 2.39; p = 0.02 and p<0.001 respectively) and the KDIGO risk classification (high-risk OR = 2.46 and very high-risk OR = 3.39; p <0.001 for both). The KDIGO risk classification is useful to screen for the presence of HF in T2DM patients. Therefore, we believe that it is necessary to carry out a systematic screening for HF in the high-and very high-risk KDIGO categories. © 2021 by the authors. Li-censee MDPI, Basel, Switzerland.
000112760 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000112760 590__ $$a4.964$$b2021
000112760 592__ $$a1.04$$b2021
000112760 594__ $$a4.4$$b2021
000112760 591__ $$aMEDICINE, GENERAL & INTERNAL$$b55 / 172 = 0.32$$c2021$$dQ2$$eT1
000112760 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000112760 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112760 700__ $$aRodríguez-Padial, L.
000112760 700__ $$aAnguita-Sánchez, M.
000112760 700__ $$aBarrios, V.
000112760 700__ $$aMuñiz, J.
000112760 700__ $$aPérez, A.
000112760 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000112760 773__ $$g10, 20 (2021), 4634 [12 pp]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000112760 8564_ $$s883912$$uhttps://zaguan.unizar.es/record/112760/files/texto_completo.pdf$$yVersión publicada
000112760 8564_ $$s2807856$$uhttps://zaguan.unizar.es/record/112760/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112760 909CO $$ooai:zaguan.unizar.es:112760$$particulos$$pdriver
000112760 951__ $$a2023-05-18-16:14:25
000112760 980__ $$aARTICLE